Retrospective evaluation of epithelial-on corneal collagen cross-linking (CXL)

Poster Details

First Author: R.Rubinfeld USA

Co Author(s):    W. Trattler   J. Talamo   B. Bowman   E. Letko   G. Berdy   B. Wiley

Abstract Details

Purpose:

To evaluate the safety, efficacy, and outcomes of epithelial-on CXL in patients diagnosed with pre-Op ectatic corneal disease.

Setting:

Center for Excellence in Eye Care, Miami, Fl

Methods:

Eyes with a pre-Op diagnosis of keratoconus, pellucid marginal degeneration (PMD), post-LASIK ectasia, or post-PRK ectasia that were treated with Epi-on CXL unilaterally or bilaterally were evaluated. A minimum of 2 months follow-up was required and patients with corneal opacities and/or complications were excluded from this analysis. Outcome measures included UCVA, BSCVA, astigmatism measures, pentacam data, and topography data.

Results:

155 eyes were evaluated, 70% were male. The average age of patients was 37 and 57% of these eyes were age 35 and over. Patients had an average follow-up of 7 months (minimum of 2 months, maximum of 20 months). 76% of eyes had a pre-Op diagnosis of keratoconus, 2.6% of eyes had a pre-Op diagnosis of PMD and of post-PRK ectasia, and 17.4% had a pre-Op diagnosis of post-LASIK ectasia. The percent of patients with a UCVA of 20/50 or better and 20/40 or better increased from 11% to 25% and 10% to16, respectively, at the latest post-Op visit. The percent of patients with a BSCVA of 20/40 or better and 20/30 or better increased from 61% to 68% and 35% to 44%, respectively, at the latest post-Op visit. 68%, 61%, and 69% of eyes had a reduction of 0.5D or more in astigmatism, spherical equivalent, and 2mm astigmatism, respectively. 43% and 56% of eyes experienced reduction in Holladay mean K and Magellan mean K, respectively. 53% of eyes experienced improvement in topography I_S ratio of 0.1D or more. 38% of eyes had a reduction in Pachymetry apex of 5 microns or more on pentacam.

Conclusions:

Epithelial-On CXL is proven safe and effective for patients diagnosed with pre-Op corneal ectatic disease. FINANCIAL DISCLOSURE?: ... has significant investment interest in a company producing, developing or supplying product or procedure presented, ... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented